

**PATENT COOPERATION TREATY**  
**PCT**  
**INTERNATIONAL SEARCH REPORT**  
(PCT Article 18 and Rules 43 and 44)

|  |   |  |
|--|---|--|
| Applicant's or agent's file reference<br><b>064016356913</b> | <b>FOR FURTHER<br/>ACTION</b>   | see Form PCT/ISA/220<br>as well as, where applicable, item 5 below                 |
| International application No.<br><b>PCT/CA2005/000042</b>    | International filing date ( <i>day/month/year</i> )<br>14 January 2005 (14-01-2005) | (Earliest) Priority date ( <i>day/month/year</i> )<br>15 January 2004 (15-01-2004) |
| Applicant<br><b>MOUNT SINAI HOSPITAL ET AL</b>               |   |  |

This international search report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau.

This international search report consists of a total of 5 sheets.

☒ It is also accompanied by a copy of each prior art document cited in this report.

1. **Basis of the report**
  - a. With regard to the **language**, the international search was carried out on the basis of the international application in the language in which it was filed, unless otherwise indicated under this item.

☐ The international search was carried out on the basis of a translation of the international application furnished to this Authority (Rule 23.1(b)).
  - b. ☒ With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, see Box No. I.
2. ☒ **Certain claims were found unsearchable** (see Box No. II).
3. ☐ **Unity of invention is lacking** (see Box No. III).
4. With regard to the **title**,

☒ the text is approved as submitted by the applicant.

☐ the text has been established by this Authority to read as follows :
5. With regard to the **abstract**,

☒ the text is approved as submitted by the applicant.

☐ the text has been established, according to Rule 38.2(b), by this Authority as it appears in Box No. IV. The applicant may, within one month from the date of mailing of this international search report, submit comments to this Authority.
6. With regard to the **drawings**,
  - a. the figure of the **drawings** to be published with the abstract is Figure No. 1

☒ as suggested by the applicant.

☐ as selected by this authority, because the applicant failed to suggest a figure.

☐ as selected by this Authority, because this figure better characterizes the invention.
  - b. ☐ none of the figures is to be published with the abstract.

**Box No. I      Nucleotide and/or amino acid sequence(s) (Continuation of item 1.b of the first sheet)**

1. With regard to any nucleotide and/or amino acid sequence disclosed in the international application and necessary to the claimed invention, the international search was carried out on the basis of:
  - a. type of material
    - ☒ a sequence listing
    - ☐ table(s) related to the sequence listing
  - b. format of material
    - ☒ in written format
    - ☒ in computer readable form
  - c. time of filing/furnishing
    - ☒ contained in the international application as filed.
    - ☒ filed together with the international application in computer readable form.
    - ☐ furnished subsequently to this Authority for the purposes of search.
2. ☒ In addition, in the case that more than one version or copy of a sequence listing and/or table relating thereto has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that in the application as filed or does not go beyond the application as filed, as appropriate, were furnished.
3. Additional comments :

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/CA2005/000042**Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of the first sheet)**

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons :

1. ☒ Claim Nos. : 1 to 16, 20 to 38

because they relate to subject matter not required to be searched by this Authority, namely :

Although claims 1 to 16 and 20 to 38 encompass either a method of treatment of the human/animal body or a method of doing business which this Authority is not obliged to search under Rule 39.1 (iii) and Rule 39.1(iv) of the PCT, the search has been carried out based on the alleged effects of PSF as a steroid receptor repressor.

2. ☐ Claim Nos. :

because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically :

3. ☐ Claim Nos. :

because they are dependant claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

**Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)**

This International Searching Authority found multiple inventions in this international application, as follows :

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claim Nos. :
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claim Nos. :

**Remark on Protest** ☐ The additional search fees were accompanied by the applicant's protest.

☐ No protest accompanied the payment of additional search fees.

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/CA2005/000042

## A. CLASSIFICATION OF SUBJECT MATTER

IPC(7): C07K 14/72; A61K 48/00; A61K 31/7098; A61K 39/395; A61K 38/17; A61K 45/00; G01N 33/566; G01N 33/567; C12Q 1/02; C12Q 1/68; A61P 15/06

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC(7): C07K 14/72; A61K 48/00; A61K 31/7098; A61K 39/395; A61K 38/17; A61K 45/00; G01N 33/566; G01N 33/567; C12Q 1/02; C12Q 1/68; A61P 15/06

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic database(s) consulted during the international search (name of database(s) and, where practicable, search terms used)

Delphion; DGene; Medline; CAPLUS search terms: polypyrimidine tract-binding protein-associated splicing factor (PSF); PTB-associated splicing factor (i.e. PSF); splicing factor proline and glutamine rich (i.e. PSF), steroid receptor modulator, progesterone withdrawal

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category* | Citation of document, with indication, where appropriate, of the relevant passages  | Relevant to claim No(s).  |
|-----------|---|---------------------------|
| X         | SPITZ, I.M. Progesterone antagonists and progesterone receptor modulators: an overview. STEROIDS 2003, Vol. 68, No. 10-13, pages 981-993<br>see whole document  | 1-12, 30-32, 34-38, 44-53 |
| A         | MCKENNA, N.J. et al. Combinatorial Control of Gene Expression by Nuclear Receptors and Coregulators. CELL 2002, Vol. 108, pages 465-474<br>see whole document   |                           |
| A         | MATHUR, M. et al. PSF Is a Novel Corepressor That Mediates Its Effect through Sin3A and the DNA Binding Domain of Nuclear Hormone Receptors. MOL CELL BIOL. 2001, Vol. 21, No. 7, pages 2298-2311<br>see whole document |                           |
| A         | SHAV-TAL, Y. et al. PSF and p54nrb/NonO - multi-functional nuclear proteins. FEBS LETTERS 2002, Vol. 531, pages 109-114<br>see whole document   |                           |

☒ Further documents are listed in the continuation of Box C.☐ See patent family annex.

|   |  |
|---|--|
| * Special categories of cited documents :   | "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention  |
| "A" document defining the general state of the art which is not considered to be of particular relevance  | "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone   |
| "E" earlier application or patent but published on or after the international filing date   | "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art |
| "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) | "&" document member of the same patent family  |
| "O" document referring to an oral disclosure, use, exhibition or other means  |  |
| "P" document published prior to the international filing date but later than the priority date claimed  |  |

Date of the actual completion of the international search

12 April 2005 (12-04-2005)

Date of mailing of the international search report

02 June 2005 (02-06-2005)

Name and mailing address of the ISA/CA  
Canadian Intellectual Property Office  
Place du Portage I, C114 - 1st Floor, Box PCT  
50 Victoria Street  
Gatineau, Quebec K1A 0C9  
Facsimile No.: 001(819)953-2476

Authorized officer

Cynthia Brewer (819) 997-4921

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/CA2005/000042

## C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

| Category* | Citation of document, with indication, where appropriate, of the relevant passages   | Relevant to claim No(s). |
|-----------|--|--------------------------|
| A         | CONDON, J.C. et al. A decline in the levels of progesterone receptor coactivators in the pregnant uterus at term may antagonize progesterone receptor function and contribute to the initiation of parturition. PNAS 2003, Vol. 100, No. 16, pages 9518-9523<br>see whole document |                          |
| A         | HENDERSON, D. et al. Reduced binding of progesterone receptor to its nuclear response element after human labor onset. AM J OBSTET GYNECOL. 2001, Vol. 185, pages 579-585<br>see whole document  |                          |
| A         | ISHITANI, K. et al. p54 <sup>orb</sup> acts as a transcriptional coactivator for activation function 1 of the human androgen receptor. BIOCHEM BIOPHYS RES COMMUN 2003, Vol. 306, No. 3, pages 660-665<br>see whole document   |                          |